EBD Blog

The U.S. Food and Drug Agency (FDA) has recommended that health-care professionals who prescribe one of the widely used drugs for treating Attention Deficit Disorder should switch patients to other comparable drugs. The FDA cited potential for liver damage in its alert about the drug, Cylert, and generic versions of it (pemoline). Cylert, will continue to be available through pharmacies and wholesalers until supplies are exhausted

The Agency has concluded that the overall risk of liver toxicity from Cylert and generic pemoline products outweighs the benefits of this drug. In May 2005, Abbott chose to stop sales and marketing of Cylert in the U.S. All generic companies have also agreed to stop sales and marketing of this product (Pemoline tablets and chewable tablets). Cylert is a central nervous system stimulant indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD). This product is considered second line therapy for ADHD because of its association with life threatening hepatic failure

Link to the FDA statement.